EBITDA

As Natuzzi prepares its Q3 results, the luxury furniture maker's costly bet on Italian craftsmanship faces a critical test amid a tough economy.

A public fund's major investment in Consensys, the firm behind MetaMask, signals growing institutional confidence in Web3's foundational infrastructure.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

The crypto giant reports massive growth, but a pivot to AI, operational fires, and rising debt reveal a risky strategy to reshape global computing power.

As New Jersey's cannabis market booms, Grown Rogue's one-year success reveals a potent strategy for blending craft quality with low-cost execution.

A moving company hosts a governor, revealing the complex logistics and infrastructure network profiting from America's massive wealth redistribution.

Coldwell Banker India appoints a decade-long partner as Area Developer for four southern states, a strategic move to dominate the region's booming market.

The infrastructure giant's new €800M share repurchase isn't just for shareholder value; it's a strategic move to fund future growth and acquisitions.

The junior explorer is expanding its footprint in a hot gold district. We analyze the financial mechanics, shareholder impact, and leadership incentives.

The media giant is refinancing high-cost debt to fund acquisitions and tech. Is this a savvy move to secure its future or a risky balance sheet gamble?

Clairvest's successful exit from F12.net yields a 35% IRR, showcasing a powerful growth strategy for private equity in Canada's booming MSP market.

As AI adoption surges, one firm's rigorous SOC 2 compliance offers a new blueprint for trust in an era of high-stakes data and complex cyber threats.

From biopharma to webcomics, shareholder lawsuits reveal the perils of misleading investors. A look at four companies facing legal and financial fallout.

HCIactive's SmartBenefits.ai promises AI-powered clarity for your health plan, but a major data breach reveals the high-stakes risks of this new frontier.

Alamo Group's acquisition of Petersen Industries for $166.5M isn't just another deal. It's a strategic move to dominate the waste management equipment market.

Hedge fund Balyasny Asset Management builds a 1.72% stake in JTC plc, signaling high-stakes maneuvering in the £2.3 billion takeover saga.

Amid a major corporate overhaul, Emergent BioSolutions secures a key FDA approval, signaling a new era for the firm and for U.S. biodefense strategy.

A top proxy advisory firm urges shareholders to reject Alcon's bid for STAAR Surgical, empowering an activist investor's high-stakes governance fight.

A novel drug for alcohol use disorder gets key scientific backing. It promises the benefits of psychedelics with fewer risks, shaking up a $35B market.

SAGA Metals' drill success and C$6M funding fuel a major critical mineral play in Labrador, aiming to secure North America's industrial future.